

## **Statement from Alkermes, Inc.:**

“For decades, people with mental illness have been incarcerated at disproportionately higher rates. As a result, our justice systems have become de facto mental health care systems.

“At Alkermes, we have developed a range of programs to help adults living with schizophrenia have access to our medicines in diverse settings of care – including individuals within criminal justice settings. Through our criminal justice system sampling program, samples of our medicines are made available when they are offered as part of a comprehensive program through which the criminal justice systems provide other re-entry services such as education, continuity of care plans and assessments of their programming. We believe that such a program in Maricopa County will help justice-involved individuals have access to the healthcare they need.

“It is important to recognize that more than 80% of individuals released from correctional facilities are estimated to be uninsured at the time of release. Loss of medical benefits can disrupt treatment during re-entry. A long-acting injectable (LAI) medication, such as ARISTADA® (aripiprazole lauroxil) can be an important treatment option for individuals living with schizophrenia who are re-entering the community.

“The resolution in Maricopa County allows for all doses of ARISTADA to be available for patient treatment through the Maricopa County Department of Health Services. Depending on the dose of ARISTADA prescribed, patients who participate in the program may re-enter the community fully dosed for up to two-months; allowing them to transition to care in the community.”

**Statement from Janssen Pharmaceuticals, Inc. via Kaitlin Meiser, leader, Janssen neuroscience product communications**

“We provide samples to prescribers at healthcare facilities including community mental health centers, hospitals and pharmacies in correctional facilities. Our sampling programs allow prescribers to familiarize themselves with the medicine and for patients to try the treatment and together with their healthcare provider, determine if it is the right fit for them. We conduct all sampling compliantly in accordance with the Prescription Drug Marketing Act.”

**Statement from Otsuka America Pharmaceutical, Inc., via Lucy Abreu,  
Senior Director Corporate Communications, Otsuka Pharmaceuticals  
Company**

“Otsuka offers samples of Abilify Maintena to licensed health care professionals across the U.S. who, in their independent medical judgment, determine that immediate onsite treatment of their patient with a diagnosis consistent with the product’s approved indications is warranted. Currently, Abilify Maintena is FDA approved for the treatment of adults with schizophrenia and Bipolar I Disorder.

“In some cases, the licensed healthcare professionals who request samples are working within a correctional system to treat patients with schizophrenia or Bipolar I Disorder. The program is not unique to Maricopa County corrections department. “